programmed micro-infusion pump Search Results


computer assisted nanoinject microinfusion pump  (World Precision Instruments)
90
World Precision Instruments computer assisted nanoinject microinfusion pump
Computer Assisted Nanoinject Microinfusion Pump, supplied by World Precision Instruments, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/programmed+micro-infusion+pump/pmc03614355-119-2-7?v=World+Precision+Instruments
Average 90 stars, based on 1 article reviews
computer assisted nanoinject microinfusion pump - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
programmable microinfusion pump iprecio smp310r  (Primetech Corporation)
90
Primetech Corporation programmable microinfusion pump iprecio smp310r
JDQ443 displays antitumor activity across a range of cell-derived, KRAS G12C -dependent mouse tumor models, with efficacy driven by daily AUC. A, Aggregated best tumor growth inhibition in six KRAS G12C tumor models. JDQ443 efficacy was evaluated after oral dosing of 10, 30, and 100 mg/kg/day in six human KRAS G12C -mutant CDX models in mice. NSCLC cell line models are depicted in red, whereas PDAC (MIA Paca-2) and esophageal (KYSE410) cancer cell line models are shown in blue. Data are means from 2–11 independent in vivo studies. %Regr. is percentage tumor volume regression [–(Δtreated/treated at baseline) × 100], and %T/C is percentage tumor volume growth ratio [(Δtreated/Δcontrol) × 100]. B–G, CDX-bearing mice with KRAS G12C -mutated ( C–G ) and non–G12C-mutated (NCI-441, KRAS G12V ; B ) tumors were treated orally (p.o.) with JDQ443 at the indicated doses and schedules. G, LU99 tumor–bearing mice were treated with JDQ443 by continuous intravenous infusion using a <t>programmable</t> <t>microinfusion</t> pump. H and I, Simulated population-PK/PD metrics of daily AUC of JDQ443 in mouse blood ( H ) and average free KRAS G12C levels in tumor at steady state ( I ) are correlated with the observed efficacy in LU99 (%T/C or % regression). Points correspond to the mean and the error bars to ± 1 SD of the simulated PK/PD metrics based on 100 simulations and observed efficacy metrics. *, P < 0.05 versus vehicle; #, P < 0.05 versus each other, by one-way ANOVA.
Programmable Microinfusion Pump Iprecio Smp310r, supplied by Primetech Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/programmed+micro-infusion+pump/pmc09394399-214-19-24?v=Primetech+Corporation
Average 90 stars, based on 1 article reviews
programmable microinfusion pump iprecio smp310r - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
programmable mini-pump iprecio smp200 micro infusion pump  (Primetech Corporation)
90
Primetech Corporation programmable mini-pump iprecio smp200 micro infusion pump
JDQ443 displays antitumor activity across a range of cell-derived, KRAS G12C -dependent mouse tumor models, with efficacy driven by daily AUC. A, Aggregated best tumor growth inhibition in six KRAS G12C tumor models. JDQ443 efficacy was evaluated after oral dosing of 10, 30, and 100 mg/kg/day in six human KRAS G12C -mutant CDX models in mice. NSCLC cell line models are depicted in red, whereas PDAC (MIA Paca-2) and esophageal (KYSE410) cancer cell line models are shown in blue. Data are means from 2–11 independent in vivo studies. %Regr. is percentage tumor volume regression [–(Δtreated/treated at baseline) × 100], and %T/C is percentage tumor volume growth ratio [(Δtreated/Δcontrol) × 100]. B–G, CDX-bearing mice with KRAS G12C -mutated ( C–G ) and non–G12C-mutated (NCI-441, KRAS G12V ; B ) tumors were treated orally (p.o.) with JDQ443 at the indicated doses and schedules. G, LU99 tumor–bearing mice were treated with JDQ443 by continuous intravenous infusion using a <t>programmable</t> <t>microinfusion</t> pump. H and I, Simulated population-PK/PD metrics of daily AUC of JDQ443 in mouse blood ( H ) and average free KRAS G12C levels in tumor at steady state ( I ) are correlated with the observed efficacy in LU99 (%T/C or % regression). Points correspond to the mean and the error bars to ± 1 SD of the simulated PK/PD metrics based on 100 simulations and observed efficacy metrics. *, P < 0.05 versus vehicle; #, P < 0.05 versus each other, by one-way ANOVA.
Programmable Mini Pump Iprecio Smp200 Micro Infusion Pump, supplied by Primetech Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/programmed+micro-infusion+pump/pmc05234709-56-7-14?v=Primetech+Corporation
Average 90 stars, based on 1 article reviews
programmable mini-pump iprecio smp200 micro infusion pump - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
programmable microinfusion pump  (Harvard Bioscience)
90
Harvard Bioscience programmable microinfusion pump
JDQ443 displays antitumor activity across a range of cell-derived, KRAS G12C -dependent mouse tumor models, with efficacy driven by daily AUC. A, Aggregated best tumor growth inhibition in six KRAS G12C tumor models. JDQ443 efficacy was evaluated after oral dosing of 10, 30, and 100 mg/kg/day in six human KRAS G12C -mutant CDX models in mice. NSCLC cell line models are depicted in red, whereas PDAC (MIA Paca-2) and esophageal (KYSE410) cancer cell line models are shown in blue. Data are means from 2–11 independent in vivo studies. %Regr. is percentage tumor volume regression [–(Δtreated/treated at baseline) × 100], and %T/C is percentage tumor volume growth ratio [(Δtreated/Δcontrol) × 100]. B–G, CDX-bearing mice with KRAS G12C -mutated ( C–G ) and non–G12C-mutated (NCI-441, KRAS G12V ; B ) tumors were treated orally (p.o.) with JDQ443 at the indicated doses and schedules. G, LU99 tumor–bearing mice were treated with JDQ443 by continuous intravenous infusion using a <t>programmable</t> <t>microinfusion</t> pump. H and I, Simulated population-PK/PD metrics of daily AUC of JDQ443 in mouse blood ( H ) and average free KRAS G12C levels in tumor at steady state ( I ) are correlated with the observed efficacy in LU99 (%T/C or % regression). Points correspond to the mean and the error bars to ± 1 SD of the simulated PK/PD metrics based on 100 simulations and observed efficacy metrics. *, P < 0.05 versus vehicle; #, P < 0.05 versus each other, by one-way ANOVA.
Programmable Microinfusion Pump, supplied by Harvard Bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/programmed+micro-infusion+pump/bio_rxiv__2020__11__12__378612-62-14-17?v=Harvard+Bioscience
Average 90 stars, based on 1 article reviews
programmable microinfusion pump - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
programmed micro-infusion pump  (Primetech Corporation)
90
Primetech Corporation programmed micro-infusion pump
JDQ443 displays antitumor activity across a range of cell-derived, KRAS G12C -dependent mouse tumor models, with efficacy driven by daily AUC. A, Aggregated best tumor growth inhibition in six KRAS G12C tumor models. JDQ443 efficacy was evaluated after oral dosing of 10, 30, and 100 mg/kg/day in six human KRAS G12C -mutant CDX models in mice. NSCLC cell line models are depicted in red, whereas PDAC (MIA Paca-2) and esophageal (KYSE410) cancer cell line models are shown in blue. Data are means from 2–11 independent in vivo studies. %Regr. is percentage tumor volume regression [–(Δtreated/treated at baseline) × 100], and %T/C is percentage tumor volume growth ratio [(Δtreated/Δcontrol) × 100]. B–G, CDX-bearing mice with KRAS G12C -mutated ( C–G ) and non–G12C-mutated (NCI-441, KRAS G12V ; B ) tumors were treated orally (p.o.) with JDQ443 at the indicated doses and schedules. G, LU99 tumor–bearing mice were treated with JDQ443 by continuous intravenous infusion using a <t>programmable</t> <t>microinfusion</t> pump. H and I, Simulated population-PK/PD metrics of daily AUC of JDQ443 in mouse blood ( H ) and average free KRAS G12C levels in tumor at steady state ( I ) are correlated with the observed efficacy in LU99 (%T/C or % regression). Points correspond to the mean and the error bars to ± 1 SD of the simulated PK/PD metrics based on 100 simulations and observed efficacy metrics. *, P < 0.05 versus vehicle; #, P < 0.05 versus each other, by one-way ANOVA.
Programmed Micro Infusion Pump, supplied by Primetech Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/programmed+micro-infusion+pump/pmc05099856-136-19-22?v=Primetech+Corporation
Average 90 stars, based on 1 article reviews
programmed micro-infusion pump - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
microinfusion pump  (New Era Pump Systems Inc)
96
New Era Pump Systems Inc microinfusion pump
JDQ443 displays antitumor activity across a range of cell-derived, KRAS G12C -dependent mouse tumor models, with efficacy driven by daily AUC. A, Aggregated best tumor growth inhibition in six KRAS G12C tumor models. JDQ443 efficacy was evaluated after oral dosing of 10, 30, and 100 mg/kg/day in six human KRAS G12C -mutant CDX models in mice. NSCLC cell line models are depicted in red, whereas PDAC (MIA Paca-2) and esophageal (KYSE410) cancer cell line models are shown in blue. Data are means from 2–11 independent in vivo studies. %Regr. is percentage tumor volume regression [–(Δtreated/treated at baseline) × 100], and %T/C is percentage tumor volume growth ratio [(Δtreated/Δcontrol) × 100]. B–G, CDX-bearing mice with KRAS G12C -mutated ( C–G ) and non–G12C-mutated (NCI-441, KRAS G12V ; B ) tumors were treated orally (p.o.) with JDQ443 at the indicated doses and schedules. G, LU99 tumor–bearing mice were treated with JDQ443 by continuous intravenous infusion using a <t>programmable</t> <t>microinfusion</t> pump. H and I, Simulated population-PK/PD metrics of daily AUC of JDQ443 in mouse blood ( H ) and average free KRAS G12C levels in tumor at steady state ( I ) are correlated with the observed efficacy in LU99 (%T/C or % regression). Points correspond to the mean and the error bars to ± 1 SD of the simulated PK/PD metrics based on 100 simulations and observed efficacy metrics. *, P < 0.05 versus vehicle; #, P < 0.05 versus each other, by one-way ANOVA.
Microinfusion Pump, supplied by New Era Pump Systems Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/programmed+micro-infusion+pump/pm26146890-67-22-28?v=New+Era+Pump+Systems+Inc
Average 96 stars, based on 1 article reviews
microinfusion pump - by Bioz Stars, 2026-07
96/100 stars
  Buy from Supplier
programmable microinfusion pump  (MiniMed Inc)
90
MiniMed Inc programmable microinfusion pump
JDQ443 displays antitumor activity across a range of cell-derived, KRAS G12C -dependent mouse tumor models, with efficacy driven by daily AUC. A, Aggregated best tumor growth inhibition in six KRAS G12C tumor models. JDQ443 efficacy was evaluated after oral dosing of 10, 30, and 100 mg/kg/day in six human KRAS G12C -mutant CDX models in mice. NSCLC cell line models are depicted in red, whereas PDAC (MIA Paca-2) and esophageal (KYSE410) cancer cell line models are shown in blue. Data are means from 2–11 independent in vivo studies. %Regr. is percentage tumor volume regression [–(Δtreated/treated at baseline) × 100], and %T/C is percentage tumor volume growth ratio [(Δtreated/Δcontrol) × 100]. B–G, CDX-bearing mice with KRAS G12C -mutated ( C–G ) and non–G12C-mutated (NCI-441, KRAS G12V ; B ) tumors were treated orally (p.o.) with JDQ443 at the indicated doses and schedules. G, LU99 tumor–bearing mice were treated with JDQ443 by continuous intravenous infusion using a <t>programmable</t> <t>microinfusion</t> pump. H and I, Simulated population-PK/PD metrics of daily AUC of JDQ443 in mouse blood ( H ) and average free KRAS G12C levels in tumor at steady state ( I ) are correlated with the observed efficacy in LU99 (%T/C or % regression). Points correspond to the mean and the error bars to ± 1 SD of the simulated PK/PD metrics based on 100 simulations and observed efficacy metrics. *, P < 0.05 versus vehicle; #, P < 0.05 versus each other, by one-way ANOVA.
Programmable Microinfusion Pump, supplied by MiniMed Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/programmed+micro-infusion+pump/pm15786474-49-6-11?v=MiniMed+Inc
Average 90 stars, based on 1 article reviews
programmable microinfusion pump - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
programmable microinfusion pump  (Bioanalytical Systems Inc)
90
Bioanalytical Systems Inc programmable microinfusion pump
JDQ443 displays antitumor activity across a range of cell-derived, KRAS G12C -dependent mouse tumor models, with efficacy driven by daily AUC. A, Aggregated best tumor growth inhibition in six KRAS G12C tumor models. JDQ443 efficacy was evaluated after oral dosing of 10, 30, and 100 mg/kg/day in six human KRAS G12C -mutant CDX models in mice. NSCLC cell line models are depicted in red, whereas PDAC (MIA Paca-2) and esophageal (KYSE410) cancer cell line models are shown in blue. Data are means from 2–11 independent in vivo studies. %Regr. is percentage tumor volume regression [–(Δtreated/treated at baseline) × 100], and %T/C is percentage tumor volume growth ratio [(Δtreated/Δcontrol) × 100]. B–G, CDX-bearing mice with KRAS G12C -mutated ( C–G ) and non–G12C-mutated (NCI-441, KRAS G12V ; B ) tumors were treated orally (p.o.) with JDQ443 at the indicated doses and schedules. G, LU99 tumor–bearing mice were treated with JDQ443 by continuous intravenous infusion using a <t>programmable</t> <t>microinfusion</t> pump. H and I, Simulated population-PK/PD metrics of daily AUC of JDQ443 in mouse blood ( H ) and average free KRAS G12C levels in tumor at steady state ( I ) are correlated with the observed efficacy in LU99 (%T/C or % regression). Points correspond to the mean and the error bars to ± 1 SD of the simulated PK/PD metrics based on 100 simulations and observed efficacy metrics. *, P < 0.05 versus vehicle; #, P < 0.05 versus each other, by one-way ANOVA.
Programmable Microinfusion Pump, supplied by Bioanalytical Systems Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/programmed+micro-infusion+pump/pm15739562-83-14-17?v=Bioanalytical+Systems+Inc
Average 90 stars, based on 1 article reviews
programmable microinfusion pump - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

Image Search Results


JDQ443 displays antitumor activity across a range of cell-derived, KRAS G12C -dependent mouse tumor models, with efficacy driven by daily AUC. A, Aggregated best tumor growth inhibition in six KRAS G12C tumor models. JDQ443 efficacy was evaluated after oral dosing of 10, 30, and 100 mg/kg/day in six human KRAS G12C -mutant CDX models in mice. NSCLC cell line models are depicted in red, whereas PDAC (MIA Paca-2) and esophageal (KYSE410) cancer cell line models are shown in blue. Data are means from 2–11 independent in vivo studies. %Regr. is percentage tumor volume regression [–(Δtreated/treated at baseline) × 100], and %T/C is percentage tumor volume growth ratio [(Δtreated/Δcontrol) × 100]. B–G, CDX-bearing mice with KRAS G12C -mutated ( C–G ) and non–G12C-mutated (NCI-441, KRAS G12V ; B ) tumors were treated orally (p.o.) with JDQ443 at the indicated doses and schedules. G, LU99 tumor–bearing mice were treated with JDQ443 by continuous intravenous infusion using a programmable microinfusion pump. H and I, Simulated population-PK/PD metrics of daily AUC of JDQ443 in mouse blood ( H ) and average free KRAS G12C levels in tumor at steady state ( I ) are correlated with the observed efficacy in LU99 (%T/C or % regression). Points correspond to the mean and the error bars to ± 1 SD of the simulated PK/PD metrics based on 100 simulations and observed efficacy metrics. *, P < 0.05 versus vehicle; #, P < 0.05 versus each other, by one-way ANOVA.

Journal: Cancer Discovery

Article Title: Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRAS G12C

doi: 10.1158/2159-8290.CD-22-0158

Figure Lengend Snippet: JDQ443 displays antitumor activity across a range of cell-derived, KRAS G12C -dependent mouse tumor models, with efficacy driven by daily AUC. A, Aggregated best tumor growth inhibition in six KRAS G12C tumor models. JDQ443 efficacy was evaluated after oral dosing of 10, 30, and 100 mg/kg/day in six human KRAS G12C -mutant CDX models in mice. NSCLC cell line models are depicted in red, whereas PDAC (MIA Paca-2) and esophageal (KYSE410) cancer cell line models are shown in blue. Data are means from 2–11 independent in vivo studies. %Regr. is percentage tumor volume regression [–(Δtreated/treated at baseline) × 100], and %T/C is percentage tumor volume growth ratio [(Δtreated/Δcontrol) × 100]. B–G, CDX-bearing mice with KRAS G12C -mutated ( C–G ) and non–G12C-mutated (NCI-441, KRAS G12V ; B ) tumors were treated orally (p.o.) with JDQ443 at the indicated doses and schedules. G, LU99 tumor–bearing mice were treated with JDQ443 by continuous intravenous infusion using a programmable microinfusion pump. H and I, Simulated population-PK/PD metrics of daily AUC of JDQ443 in mouse blood ( H ) and average free KRAS G12C levels in tumor at steady state ( I ) are correlated with the observed efficacy in LU99 (%T/C or % regression). Points correspond to the mean and the error bars to ± 1 SD of the simulated PK/PD metrics based on 100 simulations and observed efficacy metrics. *, P < 0.05 versus vehicle; #, P < 0.05 versus each other, by one-way ANOVA.

Article Snippet: To assess the effect of continuous dosing on tumor growth, LU99 tumor–bearing nude mice were implanted subcutaneously with a programmable microinfusion pump (iPRECIO, SMP310R, Primetech Corporation) as previously described ( ).

Techniques: Activity Assay, Derivative Assay, Inhibition, Mutagenesis, In Vivo